Abstract
This analysis evaluated the effect of semaglutide 2.4 mg versus placebo or semaglutide 1.0 mg on cardiometabolic risk in STEP 2. STEP 2 (NCT03552757), a double-blind, placebo-controlled trial, included 1,210 patients with overweight or obesity and type 2 diabetes randomized 1:1:1 to receive 68 weeks’ once-weekly semaglutide 2.4 mg, 1.0 mg or placebo, plus lifestyle intervention. Primary endpoints included percent change in body weight. Secondary endpoints included change in cardiometabolic risk factors.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
